293 related articles for article (PubMed ID: 33499314)
1. Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.
Cippitelli M; Stabile H; Kosta A; Petillo S; Gismondi A; Santoni A; Fionda C
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499314
[TBL] [Abstract][Full Text] [Related]
2. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
[TBL] [Abstract][Full Text] [Related]
3. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.
Fedele PL; Willis SN; Liao Y; Low MS; Rautela J; Segal DH; Gong JN; Huntington ND; Shi W; Huang DCS; Grigoriadis G; Tellier J; Nutt SL
Blood; 2018 Nov; 132(20):2166-2178. PubMed ID: 30228232
[TBL] [Abstract][Full Text] [Related]
4. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
5. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
6. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
7. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Kim GW; Yoo J; Won HR; Yeon SK; Lee SW; Lee DH; Jeon YH; Kwon SH
Leuk Res; 2020 Aug; 95():106398. PubMed ID: 32512378
[TBL] [Abstract][Full Text] [Related]
8. HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Won HR; Lee DH; Yeon SK; Ryu HW; Kim GW; Kwon SH
Int J Oncol; 2019 Aug; 55(2):499-512. PubMed ID: 31268156
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
10. Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.
Hung KH; Su ST; Chen CY; Hsu PH; Huang SY; Wu WJ; Chen MJ; Chen HY; Wu PC; Lin FR; Tsai MD; Lin KI
Cell Death Differ; 2016 Jul; 23(7):1175-84. PubMed ID: 26823144
[TBL] [Abstract][Full Text] [Related]
11. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Ocio EM; Fernández-Lázaro D; San-Segundo L; López-Corral L; Corchete LA; Gutiérrez NC; Garayoa M; Paíno T; García-Gómez A; Delgado M; Montero JC; Díaz-Rodríguez E; Mateos MV; Pandiella A; Couto S; Wang M; Bjorklund CC; San-Miguel JF
Leukemia; 2015 Mar; 29(3):705-14. PubMed ID: 25102946
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1/NK cell transdifferentiation.
Mazzurana L; Forkel M; Rao A; Van Acker A; Kokkinou E; Ichiya T; Almer S; Höög C; Friberg D; Mjösberg J
Eur J Immunol; 2019 Sep; 49(9):1344-1355. PubMed ID: 31151137
[TBL] [Abstract][Full Text] [Related]
13. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
[TBL] [Abstract][Full Text] [Related]
14. The Ikaros family in lymphocyte development.
Heizmann B; Kastner P; Chan S
Curr Opin Immunol; 2018 Apr; 51():14-23. PubMed ID: 29278858
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
16. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
17. Ikaros Zinc Finger Transcription Factors: Regulators of Cytokine Signaling Pathways and CD4
Powell MD; Read KA; Sreekumar BK; Oestreich KJ
Front Immunol; 2019; 10():1299. PubMed ID: 31244845
[TBL] [Abstract][Full Text] [Related]
18. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
19. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
20. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]